| 000 | 01601 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250513200548.0 | ||
| 264 | 0 | _c20000224 | |
| 008 | 200002s 0 0 eng d | ||
| 022 | _a0306-5251 | ||
| 024 | 7 |
_a10.1046/j.1365-2125.2000.00105.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBegg, E J | |
| 245 | 0 | 0 |
_aThe pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing. _h[electronic resource] |
| 260 |
_bBritish journal of clinical pharmacology _cJan 2000 |
||
| 300 |
_a32-8 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAnti-Infective Agents _xadverse effects |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 |
_aBronchiectasis _xmetabolism |
| 650 | 0 | 4 |
_aBronchitis _xmetabolism |
| 650 | 0 | 4 | _aChronic Disease |
| 650 | 0 | 4 |
_aCiprofloxacin _xadverse effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFleroxacin _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aModels, Biological |
| 650 | 0 | 4 |
_aSputum _xmetabolism |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aRobson, R A | |
| 700 | 1 | _aSaunders, D A | |
| 700 | 1 | _aGraham, G G | |
| 700 | 1 | _aButtimore, R C | |
| 700 | 1 | _aNeill, A M | |
| 700 | 1 | _aTown, G I | |
| 773 | 0 |
_tBritish journal of clinical pharmacology _gvol. 49 _gno. 1 _gp. 32-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1046/j.1365-2125.2000.00105.x _zAvailable from publisher's website |
| 999 |
_c10562822 _d10562822 |
||